EVOLUTION OF ANDROGEN DEPRIVATION THERAPY

被引：0
|
作者：
Raj, Ganesh V. [1 ]
Selth, Luke A. [2 ,3 ]
Day, Tanya K. [2 ,3 ]
Tilley, Wayne D. [2 ,3 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[2] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Discipline Med, Adelaide, SA 5005, Australia
[3] Univ Adelaide, Sch Med, Freemasons Fdn Ctr Mens Hlth, Adelaide, SA 5005, Australia
来源：
CANCER FORUM | 2015年 / 39卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signalling-targeted therapies in clinical development.
引用
收藏
页码：189 / 194
页数：6
相关论文
共 50 条
  • [41] Androgen Deprivation Therapy and Risk of Dementia
    Nead, K. T.
    Gaskin, G.
    Chester, C.
    Swisher-McClure, S. D.
    Leeper, N. J.
    Shah, N. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S185 - S185
  • [42] Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study
    Zhenglin Yi
    Huihuang Li
    Mingyong Li
    Jiao Hu
    Zhiyong Cai
    Zhi Liu
    Chunyu Zhang
    Chunliang Cheng
    Yunbo He
    Jinbo Chen
    Xiongbing Zu
    Ruizhe Wang
    World Journal of Urology, 42 (1)
  • [43] Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
    Stensland, Kristian D.
    Devasia, Theresa
    Caram, Megan E., V
    Chapman, Christina
    Zaslavsky, Alexander
    Morgan, Todd M.
    Hollenbeck, Brent K.
    Sparks, Jordan B.
    Burns, Jennifer
    Vedapudi, Varsha
    Duchesne, Gillian M.
    Tsodikov, Alexander
    Skolarus, Ted A.
    JNCI CANCER SPECTRUM, 2022, 6 (03)
  • [44] Androgen Deprivation Therapy and Acute Kidney Injury
    Smith, Matthew R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (21): : 2313 - 2313
  • [45] Assessment of Men Before Androgen Deprivation Therapy
    Maroni, Paul
    Crawford, E. David
    JOURNAL OF UROLOGY, 2011, 186 (02): : 371 - 372
  • [46] Androgen deprivation therapy for precancerous lesions of the prostate
    Hull, David
    Bostwick, David G.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (02) : 285 - 291
  • [47] Androgen deprivation therapy and the risk of subsequent keratitis
    Liu, Dai-Wei
    Hsu, Ren-Jun
    Huang, Sheng-Yao
    Liao, Yen-Hsiang
    Wu, Chen-Ta
    Hsu, Wen-Lin
    TZU CHI MEDICAL JOURNAL, 2021, 33 (01): : 55 - 60
  • [48] miRNAs and androgen deprivation therapy for prostate cancer
    Konoshenko, Maria Yu
    Bryzgunova, Olga E.
    Laktionov, Pavel P.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [49] Regarding Sequencing of Androgen-Deprivation Therapy
    Abner, Anthony
    Vicini, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) : 2448 - +
  • [50] Androgen deprivation therapy: past, present and future
    Schroeder, F.
    Crawford, E. D.
    Axcrona, K.
    Payne, H.
    Keane, T. E.
    BJU INTERNATIONAL, 2012, 109 : 1 - 12
12345